Clinical trials: HSV-2
Genital Herpes
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
To evaluate the efficacy of two dose levels of UB-621 administration in reducing the HSV-2 genital shedding rate in patients with recurrent genital HSV-2 infection.
- Trial name
- NCT03595995
- Testing
- UB-621
- Volunteers
- 80 people
- Sponsor
- United BioPharma
Herpes Genitalis
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more…
- Trial name
- NCT00158860
- Testing
- Valaciclovir
- Where
- 72 sites in United States, Argentina and 3 more
- Volunteers
- 384 people
- Sponsor
- GlaxoSmithKline
Herpes, Herpes Simplex
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
This study examined the efficacy, safety and benefits of modern treatment and changes in the dynamics of the life of adult patients quality with severe herpes simplex in the current medical practice when combined therapy by…
- Conditions
- Herpes, Herpes Simplex, Herpes Oral, Herpes Simplex 2
- Trial name
- NCT04664127
- Testing
- Kagocel+Valacyclovir, Valacyclovir
- Where
- Russia
- Volunteers
- 45 people
- Sponsor
- Nearmedic Plus LLC
Herpes Simplex Virus 2
HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population
This study is designed to compare the performance of the Focus Diagnostics' HerpeSelect® Express, a Herpes Simplex Virus 2 Rapid Test, to a currently marketed device.
- Trial name
- NCT00655434
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Focus Diagnostics, Inc.
Genital Herpes Simplex Type 2
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
This is a randomized, double-blind, factorial study to compare the reduction in viral shedding among 6 different combinations of GEN-003, a therapeutic HSV-2 vaccine and Matrix-M2 adjuvant.
- Trial name
- NCT02114060
- Testing
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg)
- Where
- 16 sites in United States
- Volunteers
- 310 people
- Sponsor
- Genocea Biosciences, Inc.
Genital Herpes Simplex Type 2
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
This study evaluates the reduction in viral shedding after vaccination with a new formulation of GEN-003 in subjects with genital HSV-2 infection.
- Trial name
- NCT02515175
- Testing
- Matrix-M2, GEN-003
- Where
- 8 sites in United States
- Volunteers
- 131 people
- Sponsor
- Genocea Biosciences, Inc.
Genital Herpes
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
This is a randomized, multi-center, sequential, dose-escalating study of three dose cohorts of AG-707. Individuals who meet all of the inclusion and exclusion criteria for eligibility will be randomized to receive either AG-707…
- Trial name
- NCT00231049
- Testing
- AG-707
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Agenus Inc.
Herpes Labialis
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
- Trial name
- NCT00306293
- Testing
- valacyclovir
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
HSV-2 Infection, Genital Herpes
The VIBLOK SAfety and perFormancE Trial
Genital herpes has a high prevalence in industrialized as well as developing countries. Genital herpes causes genital ulcers, increases risk for acquiring HIV infection, and may be transmitted mother to child during birth with…
- Trial name
- SAFE (NCT03080961)
- Testing
- VIBLOK barrier cream
- Where
- 3 sites in Netherlands
- Volunteers
- 82 people
- Sponsor
- CLJI Worldwide
Herpes Simplex
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of Herpes Simplex Virus (HSV)-Targeted Immunotherapy (HSVTI) in HSV-2 seronegative ethnic Japanese adults aged 18-40 years.
- Trial name
- TH HSV REC-004 (NCT05989672)
- Testing
- HSVTI Formulation 1, HSVTI Formulation 2
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Colorectal Carcinoma
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
This is a prospective, multicenter, open, randomized controlled Phase II clinical study to evaluate the efficacy and safety of intratumoral injection of OH2 combined with capecitabine for first-line maintenance of advanced…
- Trial name
- NCT05648006
- Testing
- OH2, Capecitabine, Bevacizumab
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Recurrent Genital Herpes
Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes
To evaluate the efficacy of repeat-dose UB-621 for the recurrent genital HSV-2 infection To evaluate the safety and tolerance of repeat-dose UB-621 for the recurrent HSV-2 infection To evaluate the pharmacokinetics of repeat-dose…
- Trial name
- NCT04979975
- Testing
- UB-621 low-dose, UB-621 high-dose
- Volunteers
- 200 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
Genital Herpes
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
- Trial name
- NCT07330440
- Testing
- Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Genital Herpes Simplex Type 2
Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study
This is a voluntary study to allow subjects who received placebo while on GEN-003-002 to be randomized, in a blinded manner, to 1 of 6 active combinations of GEN-003 and Matrix-M2.
- Trial name
- NCT02300142
- Testing
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg)
- Where
- 16 sites in United States
- Volunteers
- 37 people
- Sponsor
- Genocea Biosciences, Inc.
Genital Herpes Simplex Type 2
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection.
- Trial name
- NCT02910284
- Testing
- Observational
- Where
- 13 sites in United States
- Volunteers
- 140 people
- Sponsor
- Genocea Biosciences, Inc.
HIV Infections, HSV-2 Genital Herpes
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013…
- Trial name
- NCT00740584
- Testing
- 3% SPL7013 Gel (VivaGel)
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Starpharma Pty Ltd